Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Vahid Yaghmai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1440-3332; OpenAlex author ID A5073037737; NIH RePORTER profile ID 11919870. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 2)
Trials
0
Grants
1
Labs led
0
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 5 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 grant

Papers 17

  1. Predicting Pancreatic Ductal Adenocarcinoma Occurrence Up to 10 Years in Advance Using Features of the Main Pancreatic Duct in Pre-Diagnostic CT Scans. Co-author DOI 10.3390/cancers17111886↗
  2. Dendritic cell vaccination combined with irreversible electroporation for treating pancreatic cancer-a narrative review. Co-author DOI 10.21037/atm-23-1882↗
  3. Predicting and Monitoring Immune Checkpoint Inhibitor Therapy Using Artificial Intelligence in Pancreatic Cancer. Co-author DOI 10.3390/ijms252212038↗
  4. Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Inve… Co-author DOI 10.1016/j.acra.2020.04.026↗
  5. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic canc… Co-author DOI 10.1080/2162402x.2021.1875638↗
  6. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. Co-author DOI 10.1016/j.jcyt.2019.12.001↗
  7. MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02246-7↗
  8. Dinaciclib prolongs survival in the LSL-Kras G12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma. Co-author PMID 32269732↗
  9. Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK i… Co-author PMID 32509212↗
  10. Effect of route of administration on the efficacy of dendritic cell vaccine in PDAC mice. Last author PMID 33294276↗
  11. MRI Assessment of Associations between Brown Adipose Tissue and Cachexia in Murine Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4172/2165-8048.1000301↗
  12. Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models. Co-author PMID 30949410↗
  13. Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a Kras LSL-G12D p53LSL-R172H Pdx1-Cre mouse model. Co-author PMID 31497356↗
  14. Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma. Co-author PMID 31815046↗
  15. An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2018/6314392↗
  16. Loss of intratumoral macroscopic fat in renal angiomyolipoma following chemoradiation therapy for pancreatic cancer. Last author DOI 10.1259/bjrcr.20150439↗
  17. Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT. First author DOI 10.1016/j.ijrobp.2010.05.060↗

Grants 1

  1. Developing MRI-Guided Preventive Dendritic Cell Vaccination Strategy to Avoid Post-surgical Pancreatic Cancer Recurrence and Metastasis R01CA209886↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhuoli Zhang · 13 shared papers, 1 shared grant, 2019–2026 · strength 2.96
  2. Aydın Eresen · 11 shared papers, 2019–2024 · strength 1.52
  3. Jia Ying Yang · 11 shared papers, 2019–2021 · strength 1.24
  4. Al B. Benson · 6 shared papers, 2018–2021 · strength 0.65
  5. Zigeng Zhang · 2 shared papers, 2024 · strength 0.46
  6. Guangbo Yu · 2 shared papers, 2024 · strength 0.46
  7. Su Hu · 4 shared papers, 2019–2020 · strength 0.38
  8. Liang Pan · 4 shared papers, 2019–2020 · strength 0.36
  9. Su Hu · 3 shared papers, 2020 · strength 0.32
  10. Frank H. Miller · 3 shared papers, 2011–2025 · strength 0.29
  11. Temel Tirkes · 1 shared paper, 2025 · strength 0.18
  12. Lixia Wang · 1 shared paper, 2025 · strength 0.18
  13. Camila Lopes Vendrami · 1 shared paper, 2025 · strength 0.18
  14. James Leonard Buxbaum · 1 shared paper, 2025 · strength 0.18
  15. Sehrish Javed · 1 shared paper, 2025 · strength 0.18
  16. Christie Y. Jeon · 1 shared paper, 2025 · strength 0.18
  17. Stephen Jacob Pandol · 1 shared paper, 2025 · strength 0.18
  18. Srinivas Gaddam · 1 shared paper, 2025 · strength 0.18
  19. Debiao Li · 1 shared paper, 2025 · strength 0.18
  20. Touseef Ahmad Qureshi · 1 shared paper, 2025 · strength 0.18
  21. Wolfram Goessling · 1 shared paper, 2025 · strength 0.18
  22. Yasmin Genevieve Hernandez-Barco · 1 shared paper, 2025 · strength 0.18
  23. Yaqi Zhang · 2 shared papers, 2019 · strength 0.17
  24. Yumin Li · 1 shared paper, 2020 · strength 0.11
  25. Anna Junjie Shangguan · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.